SITE014-0125

SITE014 (NLD) › SITE014-0125

SITE014-0125

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2026-01-27

enrolled

AEs

5

Serious

2

Dropout signal

–

Adverse events

5

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-22 (study day 202); relationship: NOT RELATED

mild assessed

Grade 4 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 122); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Grade 4 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-10-20 (study day 77); relationship: RELATED; serious criteria: life-threatening

severe serious assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-18 (study day 75); relationship: not assessed

mild assessed

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-10-05 (study day 62); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.